Objectives Although a majority of psoriasis patients respond to treatment with narrow band ultraviolet B radiation (TL-01) phototherapy, it is currently not possible to predict erythemal sensitivity, or to identify treatment responders. A variety of antioxidant enzymes, including the polymorphic glutathione S-transferase GSTM1 and GSTT1 genes, protect the cell from UVR-induced oxidative challenge. GSTM1 and GSTT1 are deleted in approximately 50 and 20% of the Caucasian population, respectively, and GST null genotype has been associated with increased sunburn sensitivity and reduced minimal erythemal dose (MED) after broadband UVR exposure in healthy volunteers and with susceptibility to skin cancer. Another polymorphic determinant of UVR sensitivity is the melanocortin 1 receptor (MC1R), which protects cells from UVR-induced apoptosis and photodamage. Our aim was therefore to investigate whether GST or MC1R genotype influenced erythemal sensitivity to narrow band (TL-01) ultraviolet B radiation phototherapy in patients with psoriasis.
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Methods We used TaqMan quantitative gene copy and allelic discrimination assays to determine GST and MC1R genotypes, and looked for possible associations between genotype and threshold erythemal sensitivity (MED) and treatment outcomes in patients with psoriasis (n = 256).
Results We showed that GSTM1 genotype, but not GSTT1 or MC1R genotype influences erythemal sensitivity to TL-01 phototherapy, with a significantly lower MED observed in GSTM1 null individuals [w 
Introduction
Skin disease is extremely common, with over 20% of the UK population affected at any one time. Psoriasis, a chronic, relapsing, hyper-proliferative skin disease, affects approximately 2% of the population [1] and is both a major cause of morbidity and a significant therapeutic challenge [2] . Phototherapy, using a variety of artificial sources of ultraviolet radiation (UVR) and treatment regimens, has been widely used for many years to treat moderately severe to severe psoriasis. Narrow band ultraviolet B radiation [UVB (TL-01)] phototherapy (using lamps with output peaking at approximately 311-313 nm) is now extensively used, has been shown to be more effective than broadband UVB, and is the current phototherapeutic treatment of choice for psoriasis [3, 4] . In our experience, approximately 85% of patients achieve clearance of psoriasis with a three times weekly course of TL-01 treatment administered over a 6-week period, with 50% of patients still clear 6 months later [5] . Individual patient responses to treatment are unpredictable, however, and it is currently not possible to identify those patients who will respond or relapse most rapidly, or those who will be most susceptible to the adverse effects of treatment, such as uncomfortable erythema 'burning' episodes.
Exposure of skin to UVR results in the production of highly reactive free radical species, which if unquenched can cause extensive cellular damage [6, 7] . As an adaptive response to UVR exposure, the expression of a variety of antioxidant enzymes is induced in the skin to neutralize reactive oxygen species and to protect the cell from oxidative challenge [8] [9] [10] [11] . One of the most important cellular antioxidants is glutathione, which is conjugated to reactive electrophilic species by the glutathione S-transferase enzymes (GSTs) [12, 13] . The GST gene family in man is highly polymorphic, however, and the GSTM1 and GSTT1 genes are deleted in approximately 50 and 20% of the Caucasian population, respectively, with a corresponding loss of enzyme function [14, 15] . Inheritance of 'null' GST alleles has been associated with increased susceptibility to nonmelanoma skin cancers [16, 17] and, in a small study of healthy volunteers, with cutaneous erythemal sensitivity to broadband UVB, assessed by minimal erythema dose (MED) [18] . Inheritance of null GST alleles has also been associated with increased sunburn sensitivity, and active GSTM1 and GSTT1 alleles with photosensitization after the administration of Hypericum extract (St John's wort) [19] . Both of these studies, however, have investigated the effects of broadband UVB sources and were performed in healthy volunteers; correlation of GST genotype with erythemal sensitivity to narrow band UVB (TL-01) or with treatment outcomes in patients with psoriasis has not been investigated.
The melanocortin 1 receptor (MC1R) is a highly polymorphic G protein-coupled receptor, which activates cyclic AMP-mediated signal transduction after stimulation by a variety of physiological and external stimuli, including a-melanocyte stimulating hormone and UVR [20] . More than 60 MC1R single nucleotide polymorphisms (SNPs) resulting in nonconservative amino acid substitutions have been described, and inheritance of various MC1R alleles, most notably alleles containing the Arg 151 Cys, Arg 160 Trp or Asp 294 His SNPs, has been associated with a red hair/fair skin phenotype, increased incidence of skin cancer and altered sensitivity to UVR [21, 22] . Consistent with these epidemiological studies, MC1R has been shown to protect cells from UVR-induced apoptosis and photodamage, whereas loss of MC1R function reduces the antiapoptotic effect of a-melanocyte stimulating hormone [23, 24] . We have recently showed that MC1R genotype influences sensitivity to psoralen-UVA photochemotherapy (PUVA) in patients with skin disease [25] , but the influence of MC1R genotype on TL-01 phototherapy response has not been evaluated.
We therefore investigated whether GSTM1, GSTT1 or MC1R genotype influences erythemal sensitivity or response to TL-01 phototherapy in patients with psoriasis. Recent advances in analytical techniques now allow us to identify individuals who are both homozygous and heterozygous for the GSTM1 [26] and GSTT1 [27] gene deletions and to identify individuals with multiple copies and corresponding increased activity of GSTM1 [28] .
An increased understanding of the molecular mechanisms which influence how individual psoriasis patients respond to phototherapy might help to predict treatment outcomes and minimize the adverse effects of treatment. This study was therefore designed (i) to validate the use of quantitative TaqMan Gene Copy Number Assays to assign GSTM1 and GSTT1 genotypes, (ii) to determine whether GST genotype is associated with threshold erythemal sensitivity (determined as MED) to TL-01 in patients with psoriasis, (iii) to determine whether GST genotype is associated with psoriasis response after TL-01 treatment and (iv) to investigate whether the association we reported earlier between MC1R genotype and PUVA sensitivity [25] is also found with TL-01.
Methods

Patients
All adult Caucasian patients with psoriasis, prescribed a course of TL-01 phototherapy in Ninewells Hospital and Medical School, were invited to participate in the study. In total, 256 patients [121 men, 135 women, median age 41 (range 17-83) years] were recruited between December 2003 and May 2008. All study participants provided a 10 ml venous blood sample for genotyping analysis, which was stored in EDTA anticoagulant at -201C until further processing. Details including natural hair colour at the age of 21 years, eye colour, freckling tendency, skin phototype and duration of psoriasis were recorded. Written informed consent was obtained from all study participants and the study was approved by the Tayside Committee on Medical Research Ethics.
Minimal erythema dose testing
A calibrated bank of TL-01 lamps was used for MED testing using a geometric dose series (administered doses were 25, 50, 70, 100, 140, 200, 280 and 390 mJ/cm 2 for individuals with skin phototypes I and II; for skin phototypes III and IV, the 25 and 50 mJ/cm 2 doses were omitted and 550 and 770 mJ/cm 2 doses were included). Test sites on the back were exposed using a UVimpermeable cloth template. Monthly irradiances were monitored to allow accurate dosimetry and calibration was traceable to the United Kingdom National Standards maintained by the National Physics laboratory. Erythemal responses were assessed 24 h after irradiation by visual MED, defined as the UVB dose required to elicit just perceptible erythema [28] .
TL-01 treatment and assessment of responses
Treatment was carried out using either a Waldmann UV 5000 cabinet (Waldmann, Villingen-Schwenningen, Germany), fitted with 24 Philips 100 W TL-01 lamps (Philips Lighting, Eindhoven, The Netherlands), or a Ninewells Medical Physics Department constructed cabinet with 50 Philips 100 W TL-01 lamps. Irradiance measurements and calibration were performed as described above for MED testing. Patients were treated with a three times weekly TL-01 regime until clearance (no palpable psoriasis remaining) or minimal residual activity (MRA), defined as trace disease, below knees or on sacrum only. To maximize the chance of achieving complete clearance, treatment was stopped either at clearance, or after the fourth treatment at which MRA was documented, according to our standard practice. The number of treatments, whether clearance/MRA was achieved, the reduction in psoriasis severity scoring (scaling, erythema, induration) [29] by 12 treatments and the time to relapse, as defined by worsening psoriasis to the point of needing to use antipsoriatic therapies again after phototherapy treatment, were documented. Erythema episodes during treatment courses were documented as in our standard practice, with grade 1 erythema implying mild, asymptomatic erythema and grade 2-grade 4 erythema implying erythema of some importance, with grade 2 erythema being uncomfortable (but not painful, not leading to blistering or desquamation), well-demarcated, erythema.
Genotyping analysis
Genomic DNA was extracted from 200 ml whole blood using a QIAamp blood kit (Qiagen, Crawley, West Sussex, UK), according to the manufacturer's instructions and stored in Tris EDTA buffer at 41C. MC1R genotype was determined in multiplex PCR analyses as described earlier [25] , and GSTM1 and GSTT1 genotypes determined by quantitative TaqMan Gene Copy Number Assays (Applied Biosystems, Warrington, Cheshire, UK), where GSTM1 and GSTT1 copy number was compared with the copy number of the reference gene RNaseP, which is known to be present in two copies in the diploid genome. Relative quantitation values were obtained using CopyCaller Software on a 7900HT Fast Real-Time PCR system (Applied Biosystems). Gene copy number assays were additionally validated by comparison of our results with earlier published methods for GSTM1 and GSTT1 genotype determination [15, 30] .
Statistical analysis
Deviation from Hardy-Weinberg equilibrium was assessed using Pearson's w 2 -tests, comparing theoretical and observed genotype distributions. Correlations between genotype and erythemal sensitivity were assessed using nonparametric Kruskal-Wallis equality of population tests for three or more discrete variables. Genotype and patients with important (Z grade 2) erythema episodes associations were assessed using w 2 -tests. The influence of MC1R genotype on hair and eye colour, skin type and freckling tendency were assessed by Fisher's exact tests using 2 Â 2 contingency tables. Statistical significance was arbitrarily defined as P less than 0.05, without mathematical corrections made for multiple comparisons. The main psoriasis response outcome measure was taken as treatments to clearance/MRA, analysed using Cox regression analysis, with Efron's method for handling 'tied failures' (patients reaching clearance/MRA at the same number of treatments). With this sample size, the study had an estimated 86% power to detect as significant (at a = 0.05, with two-sided testing) a difference of 10% or more in percentages with a particular genotype.
Results
Patient recruitment
In total, 256 patients [121 men, 135 women, median age 41 (range 17-83) years, skin phototype I (26 patients, 10%), phototype II (133 patients, 52%), phototype III (96 patients, 38%) and phototype IV (1 patient)] were recruited between December 2003 and May 2008, representing 42.4% of all eligible patients in our recruitment period. Although more than 90% of all patients invited to participate in the study agreed to take part, limited research nurse availability meant that it was only possible to approach approximately 50% of all eligible patients.
Validation of quantitative TaqMan gene copy number assays for determining GSTM1 and GSTT1 genotypes
As the common polymorphisms in GSTM1 and GSTT1 are complete gene deletions, genotype has conventionally been determined by multiplex PCR analysis, where GSTM1 or GSTT1 is co-amplified with a control amplicon of similar size from an appropriate non-polymorphic 'housekeeping' gene, for example, actin or b-globin [15, 30] . This approach allows the binary classification of GST genotype (present/absent or wild type (wt)/null), but does not permit the identification of heterozygous individuals, that is, the assay does not distinguish between individuals with one or two copies of the GSTM1 and GSTT1 genes.
To provide a more quantitative assessment of GST genotype, we used TaqMan Gene Copy Number Assays, in which the expression of GSTM1 and GSTT1 is compared with the control gene RNase P, which is known to have two copies in the diploid genome. As illustrated in Fig. 1a and b, gene copy number assays allowed us to identify individuals with 0, 1 and 2 (or more) copies of the GSTM1 and GSTT1 genes, respectively, and to show that the allele distributions were in Hardy-Weinberg equilibrium for both GSTM1 and GSTT1. Lack of detectable deviation from Hardy-Weinberg equilibrium indicates that neither GSTM1 (P = 0.51) nor GSTT1 (P = 0.81) genotypes has major independent influences on psoriasis risk. No individuals with a GSTM1 or GSTT1 gene amplification (i.e. > 2 gene copies) were identified in our study population. 'Present' and 'absent' genotype calls were in complete agreement using conventional multiplex PCR and gene copy number analysis for both genes (data not shown).
Glutathione S-transferase genotype and erythemal sensitivity
To determine whether GST genotype influenced erythemal sensitivity in patients starting TL-01 phototherapy, MED were compared in the various genotype groups (Fig. 2) . Consistent with earlier data on broadband UVB responses, GSTM1 genotype was associated with MED (P = 0.013), where median MED was slightly, but significantly, higher in patients with two active GSTM1 alleles than in those with zero or one gene copy (95% confidence interval for difference in medians 110 to almost 0 mJ/cm 2 , P = 0.003). There was no detectable difference in MED when individuals with one and two gene copies (considered in earlier analyses as a single 'wild type' group) were compared with the GSTM1 null group (P = 0.64). The number of patients, treated with regimens based initially on individual MEDs, experiencing potentially important ( Z grade 2) erythema during a treatment course did not detectably vary according to GSTM1 genotype (P = 0.80). In contrast to GSTM1, GSTT1 genotype showed no detectable association with MED (P = 0.77).
Glutathione S-transferase genotype and treatment outcome
As GSTM1 genotype was associated with erythemal sensitivity, we also determined whether this genotype was associated with treatment response, assessed as the probability of achieving clearance/MRA according to number of treatments. Neither GSTM1 (P = 0.26) nor GSTT1 (P = 0.86) genotype was significantly associated with number of treatments to clearance/MRA (Fig. 3) , and treatment outcomes were not modified by hair/eye colour or skin phototype (data not shown).
Influence of MC1R genotype on erythemal sensitivity
As we have reported earlier that MC1R genotype is associated with PUVA erythemal sensitivity, we further investigated whether a similar association was seen in patients treated with TL-01 phototherapy. Four MC1R SNPs were analysed (Val 60 Leu, Met 92 Val, Arg 151 Cys and Arg 163 Gln), as genetic variation at these loci has been associated earlier with UVR sensitivity and/or with a red hair/fair skin phenotype [21, 22] . No significant associations with MED were observed (Fig. 4) , although there was a suggestion that the MC1R Arg 151 Cys SNP may have some association with erythemal response, with lower (but not statistically significant, P = 0.196) MED values in rare allele homozygotes. Consistent with earlier literature, we found significant associations between MC1R genotype and hair colour, eye colour, freckling tendency and skin phototype (Table 1 ). In contrast, MED was associated with hair colour, assessed as both red hair (P = 0.039) and red/fair hair (P = 0.036), but not with eye colour (P = 0.214), freckling tendency Glutathione S-transferase M1 (GSTM1) and GSTT1 genotype analysis. Panels (a) and (b) illustrate the results of our quantitative copy number analysis of (a) GSTM1 and (b) GSTT1 genotype, performed as described in the 'Methods' section. The relative population distribution of GST alleles, expressed relative to RNAseP, is illustrated. 
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Glutathione S-transferase (GST) genotype and TL-01 erythemal sensitivity. GST genotype, determined by quantitative gene copy number analysis, was compared with erythemal sensitivity, assessed by minimal erythemal dose (MED), as described in the 'Methods' section. Results are shown graphically for (a) GSTM1 and (b) GSTT1.
(P = 0.478) or skin phototype (P = 0.757), although there was a clear reduction in MED in skin phototype I individuals. Like GSTM1 and GSTT1, MC1R genotype was not detectably associated with treatment response, and the association was not modified by hair/eye colour or by skin phototype (data not shown).
Discussion
Genetically determined variation in response to UVR challenge has been reported earlier [31] [32] [33] [34] [35] , and GST and MC1R genotypes have been consistently associated with increased risk of non-melanoma skin cancers [16] , including in transplant patients [17, 36, 37] and melanoma [38, 39] . Although UVR is universally recognized as a complete carcinogen, controlled exposure to artificial sources of UVR is routinely used in clinical practise for the treatment of psoriasis and other common skin diseases. Identification of genetic determinants of treatment sensitivity and/or response might, therefore, prove 
Glutathione S-transferase (GST) genotype and treatment outcome. GST genotype, determined by quantitative gene copy number analysis, was compared with treatment outcome, assessed as the probability of achieving clearance (minimal residual activity) according to number of treatments, as described in the 'Methods' section. The results of Cox regression analysis, represented as Kaplan-Meier survival plots, are presented for (a) GSTM1 and (b) GSTT1, respectively. useful in the selection of the most appropriate patients for UVR phototherapy treatment, and possibly in the selection of the most appropriate UVR regimens for individual patients.
A significant technical limitation of earlier GST genotype association studies has been the inability to identify individuals heterozygous for the GSTM1 or GSTT1 gene deletions, as earlier non-quantitative PCR-based genotyping methods have simply classified individuals as wt or null. As such, null individuals were correctly classified, but it was not possible to discriminate between wt individuals inheriting either one or two gene copies. Our use of quantitative gene copy number assays showed that true wt individuals (two gene copies) were present in only 8.6% (GSTM1) and 31.1% (GSTT1) of our study population, respectively. Improved quantitative genotyping assays have, therefore, allowed us to more accurately classify GST genotype, and to investigate phenotypes associated with the inheritance of the 'intermediate' heterozygote genotype. The ability to fully discriminate GST genotypes not only makes clinical correlations more logical and more easily interpretable, but also facilitates direct comparison of the influence of GST genotype with, for example, MC1R genotype, where quantitative genotype analysis is routine. The use of gene copy number assays would have additionally allowed us to detect GSTM1 and GSTT1 gene amplification events, with associated 'ultra-rapid' enzyme activity, although these were not detected in our study population. Consistent with our findings, amplification of the GSTT1 gene has not been reported earlier, while the GSTM1 gene amplification resulting from a gene duplication event on chromosome 1p is rare, with earlier description limited to two Saudi Arabian individuals with increased metabolism of the GSTM1 substrate trans-stilbene oxide [28] .
In addition to their influence on skin cancer susceptibility, GST null genotypes have been associated earlier with broadband UVB sensitivity [18, 19] and, in small studies with limited power, with the development of systemic lupus erythematous [40] , senile cataract [41] and solar keratoses [42] . The molecular mechanisms which rationalize the role of the GST enzymes in mediating the effects of UVR-induced oxidative stress are not fully understood, although recent data highlight increased DNA fragmentation and mitochondrial DNA deletions [43] and telomere shortening [44] in GSTM1 null individuals, suggesting a direct influence on DNA integrity.
Unlike the GSTs, there are few earlier reports of associations between MC1R genotype and altered susceptibility to skin diseases other than melanoma [38, 39] and non-melanoma [45, 46] skin cancers, although we have reported earlier an association between MC1R genotype and PUVA sensitivity in patients with psoriasis [25] . As each of the common MC1R alleles contains a single amino acid change relative to the common consensus sequence, one might predict that the phenotypic consequences of inheriting variant MC1R alleles would be more subtle than associations with GST null genotypes. Although this study is significantly under-powered to investigate any potential influence of MC1R genotype on TL-01 erythemal sensitivity, our data suggest that inheritance of the MC1R Arg 151 Cys allele may, like GSTM1, be associated with reduced MED, and we highlight the importance of replicating this observation in larger independent patient series.
The influence of MC1R genotype on skin cancer susceptibility is consistently greater than risk estimates for the GST enzymes, although our data suggest that the opposite is true when considering the acute effects of UVB exposure. It is therefore important to note that, although current follow-up data is reassuring [47] , the long-term effect of repeated TL-01 UVR exposures on cancer risk has not been fully investigated. This contrast is perhaps not surprising, when one considers the physiological functions of each enzyme system. The GST enzymes form part of our rapid adaptive response mechanism to challenge by a variety of xenobiotics and UVR, where transcriptional regulation of the GST genes is regulated by a variety of transcription factors including AP1 and Keap1/ Nrf2 [48] [49] [50] [51] . It is therefore logical that loss of GST function may have a more significant influence than MC1R genotype on acute erythemal sensitivity in response to UVR challenge, in contrast to skin cancer risk, which is significantly increased after chronic cumulative UVR exposure. MC1R plays a critical role in the biosynthesis of the photoprotective barrier melanin [20] , and it is therefore possible that the influence of MC1R genotype on erythemal sensitivity is UVR wavelength dependent. Consistent with this hypothesis, we found a greater association between MC1R genotype and PUVA erythemal sensitivity than we report here in a patient cohort treated with TL-01 phototherapy. Earlier studies investigating the influence of MC1R genotype on UVR sensitivity are limited to cell line systems (e.g. [52, 53] ), which do not accurately model cutaneous UV penetration in vivo, or facilitate comparison of different UVR sources. Consistent with the findings of our earlier study in PUVA patients, we did not observe any influence of genotype on TL-01 treatment outcome, suggesting that determinants of acute erythemal sensitivity are not good predictors of treatment response using MED-based regimes.
